ADC Therapeutics Announces ZYNLONTA® Updates in Japan
Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results Tanabe Pharma entered into exclusive sublicensing agreement with Nippon Shinyaku, bringing established Japanese...